Neurocrine Biosciences PT Raised to $20.00 at MKM Partners (NBIX)
Analysts at MKM Partners upped their price objective on shares of Neurocrine Biosciences (NASDAQ:NBIX) from $17.00 to $20.00 in a research report issued to clients and investors on Friday, Stock Ratings News reports. The firm currently has a “buy” rating on the stock. MKM Partners’ price objective points to a potential upside of 17.99% from the stock’s previous close.
A number of other firms have also recently commented on NBIX. Analysts at Cowen and Company raised their price target on shares of Neurocrine Biosciences from $19.00 to $20.00 in a research note to investors on Friday. Separately, analysts at Nomura initiated coverage on shares of Neurocrine Biosciences in a research note to investors on Wednesday, January 8th. They set a “buy” rating on the stock. Finally, analysts at Morgan Stanley downgraded shares of Neurocrine Biosciences from an “overweight” rating to an “equal weight” rating in a research note to investors on Wednesday, January 8th. They now have a $16.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Neurocrine Biosciences has an average rating of “Buy” and an average price target of $19.90.
Neurocrine Biosciences (NASDAQ:NBIX) traded up 5.15% on Friday, hitting $16.95. The stock had a trading volume of 1,340,138 shares. Neurocrine Biosciences has a 1-year low of $8.57 and a 1-year high of $20.29. The stock has a 50-day moving average of $15.48 and a 200-day moving average of $12.49. The company’s market cap is $1.141 billion. Neurocrine Biosciences also saw a significant growth in short interest during the month of January. As of January 15th, there was short interest totalling 4,989,218 shares, a growth of 23.7% from the December 31st total of 3,806,016 shares. Approximately 7.5% of the shares of the company are sold short. Based on an average daily trading volume, of 3,311,505 shares, the short-interest ratio is presently 1.5 days.
Neurocrine Biosciences (NASDAQ:NBIX) last released its earnings data on Thursday, February 6th. The company reported ($0.16) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.17) by $0.01. The company had revenue of $0.73 million for the quarter, compared to the consensus estimate of $0.79 million. During the same quarter in the prior year, the company posted $0.14 earnings per share. The company’s quarterly revenue was down 96.7% on a year-over-year basis. Analysts expect that Neurocrine Biosciences will post $-0.41 EPS for the current fiscal year.
Neurocrine Biosciences, Inc (NASDAQ:NBIX) discovers, develops and commercializes drugs for the treatment of neurological and endocrine-related diseases and disorders.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.